Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Model No.: CAS 943319-70-8
Brand: HAOHONG
Place Of Origin: China
Types Of: Pharmaceutical Intermediates
Phasical State: Solid Powder
PSA: 65.77000
LOGP: 4.40480
Color: Light Yellow
CAS No.: 943319-70-8
Molecular Formula: C29h27f3n6o
Molecular Weight: 532.55900
Density: 1.292 G/Cm3
Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM
Productivity: 1MT/YEAR
Transportation: Ocean,Air
Place of Origin: SHANDONG,CHINA
Supply Ability: 100KG/MONTH
Port: NANJING PORT,SHANGHAI PORT,BEIJING PORT
Payment Type: L/C,T/T,Paypal,Western Union
Incoterm: FOB,CIF,CPT,CIP
Product Name:
Ponatinib;
AP24534(Ponatinib);
Iclusig;
PONATINIB;
3-(2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;
3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;
Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
The United States Food and Drug Administration approved the drug as a candidate in December 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug.
In the US it can cost $138,000 a year which has been criticised.
We, Shandong Haohong Biotechnology Co., Ltd. are manufacture of API and intermediates, Ponatinib is our top strong project.
API name: Ponatinib Intermediate CAS No.: 943319-70-8
We can offer best quality product with perfect service, full documents support, factory audit is availbale.
Purity HPLC:> 99%
Water contents :< 1.0%
Packing and Storage: Preserve in well-closed containers, and store at room temperature.
Our Ponatinib intermediate list is as following, we have all the below intermedites offering all year.
Here are some other items for your checking:
Cabozantinib Intermediate;Bicalutamide Intermediate;Empagliflozin Intermediate;
Enzalutamide Intermediate;Apalutamide Intermediate;Alectinib Intermediate
Package & Shipping:
1. Preferentially DHL or FedEx for quantity less than 50KG; Air shipping for 100KG above; Sea shipping for quantity over 500KG.
2. We can offer complete package from concept to delivery; arranging everything up until products arrive at your own door or distribution hub.
Our Service:
1. Supply high quality products with reasonable prices for pharmaceutical factory.
2. In time delivery, Packing pictures and loading video before loading.
3. Various documents(COA, MSDS, ROS, MOA etc.) and factory audit available.
4. Pre-sale consultation and post-sale service available.
5. Provide market informations to make customers fully informed.
Product Categories : Active Pharmaceutical Ingredient(API) > Ponatinib API
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.